Multiple Myeloma Articles

Expert Touts Value of Lenalidomide Maintenance in Myeloma
Lenalidomide as a maintenance treatment for patients with newly diagnosed symptomatic multiple myeloma demonstrated encouraging phase III findings in the Myeloma X1 trial, which were presented at the 2016 ASH Annual Meeting.
Transplant Remains Pivotal in Myeloma, Other Hematologic Cancers
The use of stem cell transplantation has changed over the last few years, with the emergence of novel therapies and treatment strategies. But even with the FDA approvals of new agents for multiple myeloma and select lymphomas, transplant remains to be a curative and reliable strategy.
Myeloma Expert Highlights Practice-Changing ASH Findings
The landscape of multiple myeloma continues to shift with more drug approvals, but pivotal results out of the 2016 ASH Annual Meeting will likely alter it even further.
Venetoclax Active in Heavily Treated Multiple Myeloma
The BCL-2 inhibitor venetoclax (Venclexta) demonstrated activity in one-fifth of patients with heavily pretreated multiple myeloma.
Benefits of Daratumumab Triplets in Myeloma Sustained With Longer Follow-Up
The benefits of 2 FDA-approved daratumumab–based triplet regimens were sustained in long-term data from 2 pivotal phase III studies presented at the 2016 ASH Annual Meeting.
Gene Expression Studies Offer Insight Into Myeloma Regimen's Efficacy
An analysis of c-MYC expression in relapsed myeloma identified subgroups of patients with improved response to the combination of an immunomodulator and a proteasome inhibitor.
Dual Transplant Prevails in Patients With Newly Diagnosed Myeloma
Patients with newly diagnosed multiple myeloma had significant improvement in progression-free survival when treated with dual versus single autologous stem-cell transplant.
Addition of Daratumumab Triples Increase in MRD Conversion in Relapsed Myeloma
The addition of daratumumab to standard-of-care regimens tripled the increase in conversion to negative minimal residual disease status in the treatment of patients with relapsed/refractory multiple myeloma.
Previously Treated Myeloma: Making Sense of Plethora of New Options

Multiple myeloma has seen significant treatment advances over the past decade. In 2015 alone, the FDA approved 5 new agents or regimens for previously treated patients.

The combination of elotuzumab, lenalidomide, and dexamethasone has excellent activity and is well-tolerated in the treatment of high-risk smoldering multiple myeloma (SMM), providing hope that it can delay or even halt progression to MM.
Publication Bottom Border
Border Publication